Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Capital Medical University · Wenzhou Medical University · +3 more institutions
Abstract
Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer's pathogenesis and progression. Aβ has been the prime target for the development of AD therapy. However, the repeated failures of Aβ-targeted clinical trials have cast considerable doubt on the amyloid cascade hypothesis and whether the development of Alzheimer's drug has followed the correct course. However, the recent successes of Aβ targeted trials have assuaged those doubts. In this review, we discussed the evolution of the amyloid cascade hypothesis over the last 30 years and summarized its application in Alzheimer's diagnosis and…
Citation impact
- FWCI
- 146.09
- Percentile
- 100%
- References
- 561
Authors
5- YZYun ZhangCorresponding
Capital Medical University
- HCHuaqiu Chen
Capital Medical University
- RLRan Li
Wenzhou Medical University, Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University
- KSKeenan Sterling
University of British Columbia
- WSWeihong SongCorresponding
University of British Columbia, Capital Medical University, Wenzhou Medical University, Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Zhejiang Lab
Topics & keywords
- Senile plaques
- Amyloid β
- Disease
- Clinical trial
- Biochemistry of Alzheimer's disease
- Alzheimer's disease
- Medicine
- Amyloid (mycology)
- Good health and well-being